Cinven to buy pharmaceutical-research contractor for $915M

Cinven has agreed to acquire Medpace, a pharmaceutical-research outsourcing company, for $915M from CCMP Capital Advisors.

Medpace has 1,500 employees in over 45 countries and generated $94M in adjusted core earnings last year.

The deal is the latest in the sector between private-equity firms. The market for companies  such as Medpace is growing, due to the increasing need of drug firms to outsource clinical studies.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs